Online citations, reference lists, and bibliographies.

Unmet Medical Needs In Pulmonary Neuroendocrine (Carcinoid) Neoplasms

Eric Baudin, Aimee R. Hayes, Jean‐Yves Scoazec, Pier Luigi Filosso, Eric T. K. Lim, Gregory A. Kaltsas, Andrea Frilling, Jie Chen, Beata Kos-Kudła, Vera Gorbunova, Bertram Wiedenmann, Els J. M. Nieveen van Dijkum, Jarosław B. Ćwikła, Jenny Falkerby, Juan W. Valle, Matthew H. Kulke, Martyn Evan Caplin
Published 2018 · Medicine, Biology
Cite This
Download PDF
Analyze on Scholarcy
Share
Pulmonary carcinoids (PCs) display the common features of all well-differentiated neuroendocrine neoplasms (NEN) and are classified as low- and intermediate-grade malignant tumours (i.e., typical and atypical carcinoid, respectively). There is a paucity of randomised studies dedicated to advanced PCs and management principles are drawn from the larger gastroenteropancreatic NEN experience. There is growing evidence that NEN anatomic subgroups have different biology and different responses to treatment and, therefore, should be investigated as separate entities in clinical trials. In this review, we discuss the existing evidence and limitations of tumour classification, diagnostics and staging, prognostication, and treatment in the setting of PC, with focus on unmet medical needs and directions for the future.
This paper references
10.1097/JTO.0b013e318197f2e7
Tumorlets, Multicentric Carcinoids, Lymph-Nodal Metastases, and Long-Term Behavior in Bronchial Carcinoids
Piero Ferolla (2009)
10.1016/J.YPAT.2012.10.040
Limited role of Ki-67 proliferative index in predicting overall short-term survival in patients with typical and atypical pulmonary carcinoid tumors
Bruce L. A. Carter (2013)
10.1097/JTO.0000000000000250
Therapeutic Priority of the PI3K/AKT/mTOR Pathway in Small Cell Lung Cancers as Revealed by a Comprehensive Genomic Analysis
Shigeki Umemura (2014)
10.1016/j.bpg.2005.04.001
Peptide receptor radionuclide therapy.
Eric Paul Krenning (2004)
10.1097/MPA.0b013e3181ec124e
The Pathologic Classification of Neuroendocrine Tumors: A Review of Nomenclature, Grading, and Staging Systems
David S Klimstra (2010)
10.1210/jc.2005-1542
The ectopic adrenocorticotropin syndrome: clinical features, diagnosis, management, and long-term follow-up.
A. Isidori (2006)
10.1200/JCO.2005.03.616
Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281.
Weijing Sun (2005)
10.1056/NEJM199210293271806
Brief report: idiopathic diffuse hyperplasia of pulmonary neuroendocrine cells and airways disease.
Samuel M. Aguayo (1992)
10.1097/PAS.0000000000000767
High-grade Neuroendocrine Carcinoma of the Lung With Carcinoid Morphology: A Study of 12 Cases
Anne Marie Quinn (2017)
10.1016/S1470-2045(17)30681-2
Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial.
Piero Ferolla (2017)
10.1159/000443167
ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site
Marianne E. Pavel (2016)
10.1016/j.lungcan.2014.08.012
Chemotherapy for locally advanced and metastatic pulmonary carcinoid tumors.
C. R. Chong (2014)
10.1136/thoraxjnl-2013-203400
Genomic landscape of non-small-cell lung cancer in smokers and never-smokers
Niruthika Sritharan (2013)
10.1159/000472717
68Gallium DOTANOC-PET Imaging in Lung Carcinoids: Impact on Patients' Management
Angela Lamarca (2017)
Neurologic complications of carcinoid. Neurology
RA Patchell (1986)
10.1016/S0022-5223(97)70182-X
Bronchopulmonary carcinoid tumors associated with Cushing's syndrome: a more aggressive variant of typical carcinoid.
Joseph B. Shrager (1997)
10.1200/JCO.2010.33.7873
Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers.
Anna Barbara Imhof (2011)
10.1038/ncomms4518
Frequent mutations in chromatin-remodeling genes in pulmonary carcinoids
Lynnette Fernandez-Cuesta (2014)
10.1158/1078-0432.CCR-06-2053
Temozolomide as Monotherapy Is Effective in Treatment of Advanced Malignant Neuroendocrine Tumors
Sara Ekeblad (2007)
10.1097/PAS.0b013e318263207c
Objective Quantification of the Ki67 Proliferative Index in Neuroendocrine Tumors of the Gastroenteropancreatic System: A Comparison of Digital Image Analysis With Manual Methods
Laura H. Tang (2012)
10.1007/978-3-642-82982-6
TNM Classification of Malignant Tumours
L. Sobin (1987)
10.1677/ERC-07-0001
Chromogranin A as a marker of neuroendocrine neoplasia: an Italian Multicenter Study.
Maria Chiara Zatelli (2007)
10.1148/rg.336135506
Spectrum of pulmonary neuroendocrine proliferations and neoplasms.
Ryo E. C. Benson (2013)
10.1097/JTO.0000000000000092
Ki-67 Antigen in Lung Neuroendocrine Tumors: Unraveling a Role in Clinical Practice
Giuseppe Pelosi (2014)
10.1378/chest.125.5_suppl.108S
Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia as a precursor to pulmonary neuroendocrine tumors.
John R Gosney (2004)
10.1212/WNL.36.6.745
Neurologic complications of carcinoid
Roy A. Patchell (1986)
Incidence and survival of neuroendocrine tumours in the Netherlands according to histological grade: experience of two decades of cancer
CM Korse (2013)
10.1111/j.1468-3083.1997.tb00196.x
Flushing: causes, investigation and clinical consequences
M. Greaves (1997)
10.1097/JTO.0b013e31818b06e3
The IASLC Lung Cancer Staging Project: Proposals for the Inclusion of Broncho-Pulmonary Carcinoid Tumors in the Forthcoming (Seventh) Edition of the TNM Classification for Lung Cancer
William D. Travis (2008)
10.1016/j.ejcts.2006.11.031
Typical and atypical carcinoid tumours: analysis of the experience of the Spanish Multi-centric Study of Neuroendocrine Tumours of the Lung.
M. García-Yuste (2007)
10.1016/j.lungcan.2003.11.016
Outcome of patients with pulmonary carcinoid tumors receiving chemotherapy or chemoradiotherapy.
L. Wirth (2004)
10.1200/JCO.2007.15.4377
One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.
James C. Yao (2008)
10.5114/aoms.2016.57577
Chromogranin A – unspecific neuroendocrine marker. Clinical utility and potential diagnostic pitfalls
Paweł Gut (2016)
10.1016/s0513-5117(08)70328-4
MGMT Gene Silencing and Benefit From Temozolomide in GlioblastomaHegi ME, Diserens A-C, Gorlia T, et al (Univ Hosp Lausanne, Switzerland; Univ Hosp Geneva; Swiss Inst for Experimental Cancer Research, Epalinges, Switzerland; et al) N Engl J Med 352:997–1003, 2005§
Ajay Verma (2006)
10.1200/JCO.2012.30.15_SUPPL.4119
PAZONET: Results of a phase II trial of pazopanib as a sequencing treatment in progressive metastatic neuroendocrine tumors (NETs) patients (pts), on behalf of the Spanish task force for NETs (GETNE)—NCT01280201.
Enrique Grande Pulido (2012)
10.1007/s00428-006-0250-1
TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system
G. Rindi (2006)
10.1002/cncr.20825
Bronchopulmonary carcinoid in multiple endocrine neoplasia type 1.
N. Sachithanandan (2005)
10.1016/j.ejcts.2010.08.036
Carcinoid lung tumors--incidence, treatment and outcomes: a population-based study.
A. Naalsund (2011)
10.1200/JCO.2007.13.6374
Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b.
J. Yao (2008)
10.1007/s00428-017-2177-0
Distinctive pathological and clinical features of lung carcinoids with high proliferation index
C. Marchiò (2017)
10.1158/1078-0432.CCR-16-2743
Long-Term Efficacy, Survival, and Safety of [177Lu-DOTA0,Tyr3]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors
T. Brabander (2017)
10.1136/thoraxjnl-2014-205899
Test performance of PET-CT for mediastinal lymph node staging of pulmonary carcinoid tumours
Holly Pattenden (2014)
parison of response evaluation in patients with gastroenteropancreatic and thoracic neuroendocrine tumors after treatment with [ 177 Lu - DOTA 0 , Tyr 3 ] octreotate
A Mariniello (2013)
10.1002/cncr.20659
Carcinoid metastasis to the brain.
R. Hlatký (2004)
10.3949/ccjm.39.2.79
Carcinoid tumors. Analysis of 61 cases, including 11 cases of carcinoid syndrome.
Van Sickle Dg (1972)
[Ectopic ACTH syndrome].
A N Tsanev (1981)
10.1043/2009-0583-RAR.1
Neuroendocrine tumors of the lung: an update.
Natasha Rekhtman (2010)
10.1677/erc.0.0100437
Genetics of neuroendocrine and carcinoid tumours.
P D Leotlela (2003)
10.1200/JCO.2014.32.3_SUPPL.281
Capecitabine plus temozolomide (CAP-TEM) in patients with advanced neuroendocrine neoplasms (NEN): An Italian multicenter retrospective analysis.
Francesca R. Spada (2014)
10.1016/1010-7940(90)90140-U
Limited and radical resection for tracheal and bronchopulmonary carcinoid tumour. Report on 227 cases.
Georgios Stamatis (1990)
10.1159/000092718
Expression of Tyrosine Kinase Receptors in Lung Carcinoids
Dan Granberg (2006)
10.1097/MD.0000000000013806
Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia
Linfang Jin (2018)
10.1007/s13277-016-5258-9
Peptide receptor radionuclide therapy: focus on bronchial neuroendocrine tumors
Giuseppe Lo Russo (2016)
10.1007/s002590100541
Somatostatin receptor sst1–sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands
J. Reubi (2001)
10.1007/s00428-012-1194-2
Phenotyping of pulmonary carcinoids and a Ki-67-based grading approach
Tina Zahel (2012)
10.1023/A:1012569909313
Experience in treatment of metastatic pulmonary carcinoid tumors.
Dan Granberg (2001)
10.1016/S0140-6736(15)00817-X
Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study
James C. Yao (2016)
10.1530/EJE-15-0968
Prevalence and clinical features of the ectopic ACTH syndrome in patients with gastroenteropancreatic and thoracic neuroendocrine tumors.
Kimberly Kamp (2016)
Carcinoid metastasis to the brain. Cancer
R Hlatky (2004)
10.1530/EJE-16-0809
Prognostic factors in ectopic Cushing's syndrome due to neuroendocrine tumors: a multicenter study.
Maria Vittoria Davi’ (2017)
10.1093/ejcts/ezx386
The utility of blood neuroendocrine gene transcript measurement in the diagnosis of bronchopulmonary neuroendocrine tumours and as a tool to evaluate surgical resection and disease progression†
P. Filosso (2018)
10.1002/path.4853
Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin‐remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D
M. Simbolo (2017)
10.1016/j.jamcollsurg.2012.08.027
Emerging approaches in the management of patients with neuroendocrine liver metastasis: role of liver-directed and systemic therapies.
S. C. Mayo (2013)
10.1016/0046-8177(95)90221-X
Typical and atypical bronchopulmonary carcinoid tumors: a clinicopathologic and KI-67-labeling study.
Valérie Costes (1995)
10.3389/fendo.2011.00020
Partitioning of Bronchopulmonary Carcinoids in Two Different Prognostic Categories by Ki-67 Score
Franco Grimaldi (2011)
10.1016/j.ejca.2012.12.022
Incidence and survival of neuroendocrine tumours in the Netherlands according to histological grade: experience of two decades of cancer registry.
C M Korse (2013)
10.1016/0003-4975(90)90085-K
Management of the ectopic ACTH syndrome due to thoracic carcinoids.
H. Pass (1990)
10.1159/000471879
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological, Nuclear Medicine and Hybrid Imaging
A. Sundin (2017)
10.1093/annonc/mdv041
Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids.
M. Caplin (2015)
10.1210/jc.2012-1230
Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1).
Rajesh V. Thakker (2012)
10.1093/ejcts/ezu495
Prognostic model of survival for typical bronchial carcinoid tumours: analysis of 1109 patients on behalf of the European Association of Thoracic Surgeons (ESTS) Neuroendocrine Tumours Working Group.
Pier Luigi Filosso (2015)
10.1097/JTO.0000000000000065
Systemic Therapy, Clinical Outcomes, and Overall Survival in Locally Advanced or Metastatic Pulmonary Carcinoid: A Brief Report
Patrick M. Forde (2014)
10.1093/ejcts/ezu404
Clinical management of atypical carcinoid and large-cell neuroendocrine carcinoma: a multicentre study on behalf of the European Association of Thoracic Surgeons (ESTS) Neuroendocrine Tumours of the Lung Working Group†.
Pier Luigi Filosso (2015)
10.1158/1078-0432.CCR-08-1476
O6-Methylguanine DNA Methyltransferase Deficiency and Response to Temozolomide-Based Therapy in Patients with Neuroendocrine Tumors
Matthew H. Kulke (2009)
10.2217/fon-2016-0092
Management of bronchial carcinoids: international practice survey among the European Society of Thoracic Surgeons.
P. Filosso (2016)
10.1245/s10434-010-1006-3
Chromogranin A—Biological Function and Clinical Utility in Neuro Endocrine Tumor Disease
Irvin Mark Modlin (2010)
Regulatory peptide receptors as molecular targets for cancer diagnosis and therapy.
Jean Claude Reubi (1997)
Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome.
Charles G. Moertel (1979)
10.1002/cncr.23542
Bronchopulmonary neuroendocrine tumors.
B. Gustafsson (2008)
10.1210/jc.2004-2527
Cushing's syndrome due to ectopic corticotropin secretion: twenty years' experience at the National Institutes of Health.
I. Ilias (2005)
10.1016/0002-9343(78)90835-5
Multiple peripheral pulmonary carcinoids and tumorlets of carcinoid type, with restrictive and obstructive lung disease.
Margaret A Miller (1978)
10.1158/1078-0432.CCR-07-1631
Bronchopulmonary Carcinoid: Phenotype and Long-term Outcome in a Single-Institution Series of Italian Patients
Massimo Rugge (2008)
10.1016/S0169-5002(05)80464-7
PD-131 The impact of stage and cell type on prognosis of pulmonary neuroendocrine tumours
Eric T. K. Lim (2005)
10.1007/s11605-009-1115-0
Non-functional Neuroendocrine Carcinoma of the Pancreas: Incidence, Tumor Biology, and Outcomes in 2,158 Patients
Jan Franko (2009)
10.1097/MPA.0b013e3181ec1380
NANETS Consensus Guideline for the Diagnosis and Management of Neuroendocrine Tumors: Well-Differentiated Neuroendocrine Tumors of the Thorax (Includes Lung and Thymus)
Alexandria T. Phan (2010)
10.1016/S1072-7515(03)00230-8
Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival.
Juan Manuel Fernández Sarmiento (2003)
10.1016/J.YSUR.2012.03.068
Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study
Thomas J. Fahey (2012)
10.1159/000113128
Quantitative Gene Expression of Somatostatin Receptors and Noradrenaline Transporter Underlying Scintigraphic Results in Patients with Neuroendocrine Tumors
Tina Binderup (2008)
10.1007/s00259-015-3190-7
Long-term results of PRRT in advanced bronchopulmonary carcinoid
A. Mariniello (2015)
10.1038/nature14664
Comprehensive genomic profiles of small cell lung cancer
J. George (2015)
10.1210/jcem.85.9.6785
Prognostic markers in patients with typical bronchial carcinoid tumors.
Dan Granberg (2000)
10.1038/bjc.2015.397
Mutational analysis of pulmonary tumours with neuroendocrine features using targeted massive parallel sequencing: a comparison of a neglected tumour group
Claudia Vollbrecht (2015)
10.1002/ijc.1473
Familial carcinoid tumors and subsequent cancers: a nation-wide epidemiologic study from Sweden.
Kari Hemminki (2001)
10.1007/s00423-015-1277-z
Surgical therapy of neuroendocrine neoplasm with hepatic metastasis: patient selection and prognosis
F. Watzka (2015)
10.1200/JCO.2007.15.9020
Activity of sunitinib in patients with advanced neuroendocrine tumors.
Matthew H. Kulke (2008)
10.1016/j.ejcts.2004.05.052
Surgical treatment of neuroendocrine tumors of the lung.
Niccolò Daddi (2004)
10.1245/s10434-015-4654-5
Meta-analysis of Liver Resection Versus Nonsurgical Treatments for Pancreatic Neuroendocrine Tumors with Liver Metastases
Chun-hui Yuan (2015)
Clinical Practice Guidelines for Multiple Endocrine Neoplasia Type 1 ( MEN 1 )
Rajesh V. Thakker (2012)
10.1210/jc.2014-2699
Somatostatin receptors in bronchopulmonary neuroendocrine neoplasms: new diagnostic, prognostic, and therapeutic markers.
Daniel Kaemmerer (2015)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar